View source for CTSC:BIDMCresources:CITMD

[[CTSC:BIDresources|Back to BIDMC Imaging Resources]]

<br>

A key area of interdisciplinary research, the CITMD is an interdepartmental center at the BIDMC. The co-founders of the CITMD are Robert E. Lenkinski, Ph.D., Professor of Radiology, and John V. Frangioni, M.D., Ph.D., Associate Professor of Medicine and Associate Professor of Radiology, both at Harvard Medical School. These laboratories ([http://research.bidmc.harvard.edu/research/ResearchPIInfo.ASP?Submit=Display&PersonID=863 Lenkinski lab], [http://www.FrangioniLab.org Frangioni lab] ) have been active in the field of molecular imaging since 1999, and are the recipients of multiple NIH, industry, and foundation peer-reviewed grants. 


Three years ago, the CITMD began building a small animal imaging facility (http://www.longwoodsaif.org/), which has now blossomed into a state-of-the-art center.  These services include multi-modality imaging, advanced data analysis, image fusion resources, and a satellite animal facility for longitudinal studies. The CITMD is establishing a first-in-human clinical trials infrastructure to translate new cancer detection technologies into the clinic for testing on patients. This structure will ensure that promising contrast agents and imaging technology are tested on patients in a safe, efficient manner.

==Mission==

The mission is to solve important clinical problems by applying first principles from chemistry and engineering. The major focus of the laboratory is on the development of imaging technology and contrast agents to see cancer at its smallest possible manifestation. We believe that Seeing is Curing—that is, if we can see cancer at an earlier stage than we now can (currently about 1 billion cells) we will have a greater likelihood of curing it.